查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1629250

神经母细胞瘤药物市场，按给药途径、类型、最终用户、国家和地区 - 2024-2032 年行业分析、市场规模、市场份额和预测

Neuroblastoma Drugs Market, By Route of Administration, By Type, By End-user, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 303 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告要点

2023 年神经母细胞瘤药物市场规模为 8.155 亿美元，2024 年至 2032 年复合年增长率为 5.80%。

神经母细胞瘤药物市场-市场动态

神经母细胞瘤的发生率上升

推动神经母细胞瘤药物市场扩张的主要驱动力之一是该疾病发生率的上升。近年来，神经母细胞瘤的诊断显着增加，尤其是在青少年族群。由于这种发病率趋势，对复杂且成功的治疗策略的需求增加了。随着诊断能力的增强和认识的提高，发现了更多病例，鼓励製药公司和研究人员加强开发新型神经母细胞瘤药物，这支持了神经母细胞瘤药物市场的扩张。

神经母细胞瘤药物市场 - 关键见解

根据我们的研究分析师分享的分析，预计全球神经母细胞瘤药物市场在预测期内（2024-2032）每年将以 5.80% 左右的复合年增长率增长

根据给药途径细分，预计注射剂类别将在 2023 年占据最大市场份额

根据最终用户细分，医院是 2023 年的领先细分市场

按地区划分，北美是 2023 年的主要收入来源

神经母细胞瘤药物市场-細項分析：

全球神经母细胞瘤药物市场根据给药途径、类型、最终用户和地区进行细分。

根据给药途径，神经母细胞瘤药物市场分为口服和注射。 2023年，注射剂类别由于其有效性、简单性以及精确施用神经母细胞瘤药物剂量的能力，在全球神经母细胞瘤药物市场中占据主导地位。注射製剂进一步促进了该类别的成长，它提供了可靠且直接的给药途径，确保了快速吸收和生物利用度，这在儿科肿瘤学中尤其重要。

按类型划分，市场分为化疗、免疫治疗、骨髓移植、类维生素A治疗、手术等。由于知识的不断增长和研究的发展，免疫疗法有望获得更持久和有效的结果，预计在神经母细胞瘤药物市场预测期内将创下最高的年复合成长率（CAGR）。免疫疗法目前占据全球最大的市场。此外，由于持续的临床试验和合作努力，该领域正在不断增长，增强了免疫疗法的势头，并将其确立为不断变化的神经母细胞瘤治疗领域的一种改变游戏规则的策略。

神经母细胞瘤药物市场 - 地理洞察

从地理来看，神经母细胞瘤药物市场广泛分布于北美、拉丁美洲、欧洲、亚太地区、中东和非洲地区。这些区域根据开展业务的国家进一步划分。

2023 年，北美在神经母细胞瘤药物市场份额中占据最大份额。据估计，2015年美国在癌症治疗上的支出超过1,900亿美元，预计到2020年这一数字将增加超过2,000亿美元。 。随着越来越多的人接受化疗和药物治疗以预防更多疾病併发症，预计该行业将会成长。

欧洲的神经母细胞瘤药物市场预计将占据第二大份额。儿童癌症发生率上升和癌症治疗费用上升是推动市场扩张的主要因素。此外，由于抗 GD2 具有位点特异性活性且对身体缺乏细胞毒性作用，因此抗 GD2 作为第一种获得许可用于治疗神经母细胞瘤的药物，需求量巨大。此外，该地区不断增长的婴儿人口以及神经母细胞瘤尖端创新疗法的开发正在推动神经母细胞瘤药物市场的扩张。此外，对神经母细胞瘤诊断和治疗的更多了解使得我们可以专注于新的肿瘤靶点，以利用细胞介导的免疫疗法开发癌症药物。

神经母细胞瘤药物市场-竞争格局：

在全球和区域范围内运营的各种竞争对手的存在，例如Y-mabs Therapeutics, Inc.、Bristol-Myers Squibb Company、MacroGenics Inc.、AstraZeneca plc、Eli Lilly and Company 等，是造成高估值的主要原因。各种各样的业务都对市场的整体动态做出了贡献，从而定义了竞争格局。现有产业巨头、新进业者和专业解决方案提供者之间对市场份额的竞争是造成这种碎片化的原因。神经母细胞瘤药物市场上的主要参与者使用收购、合作、协议和产品批准作为扩大其产品组合的重要开发策略。例如，根据商业阶段生物製药企业 Y-mAbs Therapeutics, Inc. 的说法，2023 年 5 月，巴西卫生监管局批准了 DANYELZA (naxitamab-gqgk) 40mg/10mL 注射液的商业化。在巴西，Y-mAbs 的合作伙伴 Adium Pharma SA 将销售 DANYELZA。

最新进展：

2023 年2 月：根据商业阶段生物製药新创公司Y-mAbs Therapeutics, Inc. 发布的一份声明，欧洲药品管理局批准了拟议的naxitamab 儿科研究计划。这一结论。 PIP 所针对的适应症，即復发/难治性高风险神经母细胞瘤以及骨肉瘤，是 Y-mAb 正在开发 naxitamab 的疾病。

目录

第一章：神经母细胞瘤药物市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • 依给药途径分類的神经母细胞瘤药物市场片段
    • 按类型分類的神经母细胞瘤药物市场片段
    • 最终使用者的神经母细胞瘤药物市场片段
    • 按国家/地区分類的神经母细胞瘤药物市场片段
    • 按地区分類的神经母细胞瘤药物市场片段
  • 竞争洞察

第 3 章：神经母细胞瘤药物主要市场趋势

  • 神经母细胞瘤药物市场驱动因素
    • 市场驱动因素的影响分析
  • 神经母细胞瘤药物市场限制
    • 市场限制影响分析
  • 神经母细胞瘤药物市场机会
  • 神经母细胞瘤药物市场未来趋势

第 4 章：神经母细胞瘤药物产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：神经母细胞瘤药物市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：神经母细胞瘤药物市场格局

  • 2023 年神经母细胞瘤药物市占率分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：神经母细胞瘤药物市场 - 依给药途径

  • 概述
    • 按给药途径分類的细分市场份额分析
    • 口服
    • 可注射

第 8 章：神经母细胞瘤药物市场 - 按类型

  • 概述
    • 按类型分類的细分市场占有率分析
    • 化疗
    • 免疫疗法
    • 骨髓移植
    • 类维生素A疗法
    • 手术
    • 其他的

第 9 章：神经母细胞瘤药物市场 - 按最终用户

  • 概述
    • 按最终用户分類的细分市场占有率分析
    • 医院
    • 居家护理
    • 专科诊所
    • 其他的

第 10 章：神经母细胞瘤药物市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美神经母细胞瘤药物主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模与预测（按管理途径）
    • 北美市场规模和预测（按类型）
    • 北美市场规模和预测（按最终用户）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲神经母细胞瘤药物主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模与预测（按管理途径）
    • 欧洲市场规模与预测（按类型）
    • 欧洲市场规模和预测（按最终用户）
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 英国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区神经母细胞瘤药物主要製造商
    • 亚太地区市场规模与预测（按国家）
    • 亚太地区市场规模与预测（依管理途径）
    • 亚太地区市场规模与预测（按类型）
    • 亚太地区市场规模和预测（按最终用户）
    • 印度
    • 中国
    • 韩国
    • 日本
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲神经母细胞瘤药物主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模与预测（按管理途径）
    • 拉丁美洲市场规模与预测（按类型）
    • 拉丁美洲市场规模和预测（按最终用户）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲神经母细胞瘤药物主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模及预测（按管理途径）
    • 中东和非洲市场规模及预测（按类型）
    • 中东和非洲市场规模和预测（按最终用户）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 11 章：主要供应商分析 - 神经母细胞瘤药物产业

  • 竞争仪表板
  • 公司简介
    • Y-mabs Therapeutics, Inc.
    • Bristol-Myers Squibb Company
    • MacroGenics Inc.
    • AstraZeneca plc
    • Eli Lilly and Company
    • Recordati Group
    • Cellectar Biosciences, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer Inc.
    • United Therapeutics Corporation
    • Others

第 12 章：360 度分析师视角

第 13 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV4423

REPORT HIGHLIGHT

Neuroblastoma Drugs Market size was valued at USD 815.5 Million in 2023, expanding at a CAGR of 5.80% from 2024 to 2032.

The most prevalent kind of cancer among newborns is neuroblastoma. The sympathetic nervous system's embryonic malignancy, which arises from the neuroblasts, is what causes the cancer. The malignancy spreads to the spinal cord, chest, or adrenal nerve tissues. Neuroblastoma is diagnosed before the age of five in over 90% of cases. In rare instances, prenatal ultrasounds may reveal the malignancy. The increased incidence of neuroblastoma and childhood cancer are the main causes of the neuroblastoma drug market's expansion. According to estimates, as of 2023, over 700 children in the US will receive a neuroblastoma diagnosis annually. Additionally, the neuroblastoma drugs market is expected to develop as a result of people's increased awareness of cancer diagnosis and treatment. In the upcoming years, it is anticipated that the growing number of incident instances that are age- and gender-specific will spur industry expansion.

Neuroblastoma Drugs Market- Market Dynamics

Rising Incidence of Neuroblastoma

One of the main driver driving the market expansion for neuroblastoma drugs is the rise in the disease's occurrence. Neuroblastoma diagnoses have increased noticeably in recent years, especially in juvenile populations. The need for sophisticated and successful therapeutic strategies has increased as a result of this incidence trend. Pharmaceutical firms and researchers are encouraged to step up their efforts in creating novel neuroblastoma medications as more cases are discovered due to enhanced diagnostic capabilities and more awareness, which supports the neuroblastoma drug market's expansion.

Neuroblastoma Drugs Market- Key Insights

As per the analysis shared by our research analyst, the global Neuroblastoma Drugs Market is estimated to grow annually at a CAGR of around 5.80% over the forecast period (2024-2032)

Based on the route of administration segmentation, the injectable category was predicted to show maximum market share in the year 2023

Based on end-user segmentation, the hospitals were the leading segment in 2023

On the basis of region, North America was the leading revenue generator in 2023

Neuroblastoma Drugs Market- Segmentation Analysis:

The Global Neuroblastoma Drugs Market is segmented on the basis of Route of Administration, Type, End-user, and Region.

Based on the route of administration, the neuroblastoma drugs market is segregated into Oral and Injectable. In 2023, the injectable category held a dominant market position in the worldwide neuroblastoma drugs market due to its effectiveness, ease, and capacity to administer precise amounts of neuroblastoma pharmaceuticals. Further bolstering the category growth are injectable formulations, which provide a dependable and straightforward administration route, guaranteeing quick absorption and bioavailability-particularly important in pediatric oncology.

By type, the market is divided into Chemotherapy, Immunotherapy, Bone Marrow Transplantation, Retinoid therapy, Surgery, and Others. Due to growing knowledge and research developments, immunotherapy shows promise for more lasting and effective results, and it is anticipated to record the highest compound annual growth rate (CAGR) during the neuroblastoma drugs market forecast period. Immunotherapy currently holds the largest market share worldwide. Furthermore, the segment is growing as a result of continuous clinical trials and cooperative efforts that strengthen immunotherapy's momentum and establish it as a game-changing strategy in the changing field of neuroblastoma treatment.

Neuroblastoma Drugs Market- Geographical Insights

Geographically, the Neuroblastoma Drugs Market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

North America held the greatest market share for neuroblastoma drugs in 2023. This increase is ascribed to both the rise of neuroblastoma cases and the development of technologically advanced medications. According to estimates, the United States spent more than USD 190 billion on cancer treatment in 2015, and that amount is expected to rise to over USD 200 billion in 2020. Additionally, the neuroblastoma drugs market is expanding due to rising healthcare sector spending and the approval of orphan drugs for the neuroblastoma treatment. The industry is expected to rise as more people receive chemotherapy and medication therapies to prevent more complications from the illness.

The market for neuroblastoma drugs in Europe is anticipated to hold the second-largest share. The rising incidence of childhood cancer and rising cancer treatment costs are the main factors driving the market's expansion. Additionally, due to its site-specific activity and lack of cytotoxic effects on the body, anti-GD2, the first medication licensed for the treatment of neuroblastoma, is seeing tremendous demand. Furthermore, the region's growing infant population and the creation of cutting-edge, innovative treatments for neuroblastoma are driving the neuroblastoma drugs market expansion. In addition, greater knowledge about neuroblastoma diagnosis and treatment has made it possible to concentrate on novel tumour targets for the development of cancer medications using cell-mediated immunotherapy.

Neuroblastoma Drugs Market- Competitive Landscape:

The presence of various competitors operating on a worldwide and regional scale, such as Y-mabs Therapeutics, Inc., Bristol-Myers Squibb Company, MacroGenics Inc., AstraZeneca plc, Eli Lilly and Company, and others are the main reason for the high degree of fragmentation in the neuroblastoma drugs market. A wide range of businesses that each contribute to the overall dynamics of the market defines the competitive landscape. The competition for market share among existing industry giants, newcomers, and specialist solution providers is the cause of this fragmentation. The market for neuroblastoma drugs has seen major players use acquisition, collaboration, agreement, and product approval as important developmental tactics to expand their product portfolio. For instance, in May 2023, The Brazilian Health Regulatory Agency approved the commercialization of DANYELZA (naxitamab-gqgk) 40mg/10mL injection, according to Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical business. In Brazil, Adium Pharma S.A., a partner of Y-mAbs, will sell DANYELZA.

Recent Developments:

February 2023: The European Medicines Agency approved the proposed pediatric investigation plan for naxitamab, according to a statement released by commercial-stage biopharmaceutical startup Y-mAbs Therapeutics, Inc. The Pediatric Committee expressed a favourable judgment, which led to the conclusion. The indication addressed by the PIP, relapsed/refractory high-risk neuroblastoma, as well as osteosarcoma, are the conditions for which Y-mAbs is developing naxitamab.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL NEUROBLASTOMA DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Y-mabs Therapeutics, Inc.
  • Bristol-Myers Squibb Company
  • MacroGenics Inc.
  • AstraZeneca plc
  • Eli Lilly and Company
  • Recordati Group
  • Cellectar Biosciences, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • United Therapeutics Corporation
  • Others

GLOBAL NEUROBLASTOMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Injectable

GLOBAL NEUROBLASTOMA DRUGS MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Chemotherapy
  • Immunotherapy
  • Bone Marrow Transplantation
  • Retinoid therapy
  • Surgery
  • Others

GLOBAL NEUROBLASTOMA DRUGS MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Homecare
  • Speciality Clinics
  • Other

GLOBAL NEUROBLASTOMA DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Neuroblastoma Drugs Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Neuroblastoma Drugs Market Snippet by Route of Administration
    • 2.1.2. Neuroblastoma Drugs Market Snippet by Type
    • 2.1.3. Neuroblastoma Drugs Market Snippet by End-user
    • 2.1.4. Neuroblastoma Drugs Market Snippet by Country
    • 2.1.5. Neuroblastoma Drugs Market Snippet by Region
  • 2.2. Competitive Insights

3. Neuroblastoma Drugs Key Market Trends

  • 3.1. Neuroblastoma Drugs Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Neuroblastoma Drugs Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Neuroblastoma Drugs Market Opportunities
  • 3.4. Neuroblastoma Drugs Market Future Trends

4. Neuroblastoma Drugs Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Neuroblastoma Drugs Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Neuroblastoma Drugs Market Landscape

  • 6.1. Neuroblastoma Drugs Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Neuroblastoma Drugs Market - By Route of Administration

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 7.1.2. Oral
    • 7.1.3. Injectable

8. Neuroblastoma Drugs Market - By Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Type, 2023 & 2032 (%)
    • 8.1.2. Chemotherapy
    • 8.1.3. Immunotherapy
    • 8.1.4. Bone Marrow Transplantation
    • 8.1.5. Retinoid therapy
    • 8.1.6. Surgery
    • 8.1.7. Others

9. Neuroblastoma Drugs Market - By End-user

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End-user, 2023 & 2032 (%)
    • 9.1.2. Hospitals
    • 9.1.3. Homecare
    • 9.1.4. Speciality Clinics
    • 9.1.5. Others

10. Neuroblastoma Drugs Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Neuroblastoma Drugs Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Neuroblastoma Drugs Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.8. France
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.8.4. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.8.5. France Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.9. Italy
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.9.4. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.9.5. Italy Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.10. Spain
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.10.4. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.10.5. United Kingdom Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.11. United Kingdom
      • 10.3.11.1. Overview
      • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.3. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.11.4. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.11.5. United Kingdom Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.12. Russia
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Russia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.13. Netherlands
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Netherlands Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.14. Sweden
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Sweden Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.15. Poland
      • 10.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.2. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.15.3. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Poland Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.16. Rest of Europe
      • 10.3.16.1. Overview
      • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.16.3. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.16.4. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.16.5. Rest of the Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Neuroblastoma Drugs Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.9. South Korea
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.9.4. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.9.5. South Korea Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.10. Japan
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.10.4. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.10.5. Japan Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Neuroblastoma Drugs Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Neuroblastoma Drugs Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Neuroblastoma Drugs Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Y-mabs Therapeutics, Inc.
    • 11.2.2. Bristol-Myers Squibb Company
    • 11.2.3. MacroGenics Inc.
    • 11.2.4. AstraZeneca plc
    • 11.2.5. Eli Lilly and Company
    • 11.2.6. Recordati Group
    • 11.2.7. Cellectar Biosciences, Inc.
    • 11.2.8. Teva Pharmaceutical Industries Ltd.
    • 11.2.9. Pfizer Inc.
    • 11.2.10. United Therapeutics Corporation
    • 11.2.11. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us